Research programme: FPR2 agonist - Bristol-Myers Squibb/kyorin pharmaceutical

Drug Profile

Research programme: FPR2 agonist - Bristol-Myers Squibb/kyorin pharmaceutical

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Bristol-Myers Squibb; Kyorin Pharmaceutical
  • Class Small molecules
  • Mechanism of Action FPR2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 03 Feb 2016 Preclinical trials in Inflammation in Japan (unspecified route) (Kyorin pharmaceuticals' pipeline, February 2016)
  • 09 Dec 2015 Early research in Inflammation in Japan (unspecified route)
  • 09 Dec 2015 Kyorin Pharmaceutical and Bristol-Myers Squibb enter into licensing agreement for FPR2 worldwide for undisclosed indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top